Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.

Journal of gastrointestinal cancer - 1 Dec 2024

Sasaki Akinori, Nakajima Satoru, Motomura Yasuaki

Abstract excerpt

PURPOSE: Patients with advanced cholangiocarcinoma, including gallbladder cancer, typically have a poor prognosis owing to limited effective chemotherapy options. The field of genotype-directed therapy in patients with cholangiocarcinoma is advancing. However, limited clinical data are currently available to evaluate the efficacy of molecularly targeted therapy. METHODS: Herein, we report the case of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Cholangiocarcinoma

Share to Gallbladder Neoplasms

Share to Liver Neoplasms

Share to Receptor, ErbB-2

Share to Treatment Outcome

Source

Identifiers

PMID: 39254819
DOI: 10.1007/s12029-024-01112-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.PMID 39254819Read ↗

Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burdenSemantic proximity Read ↗

Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.Semantic proximity Read ↗

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.Semantic proximity Read ↗

Biliary cancer: gateway to comprehensive molecular profiling.Semantic proximity Read ↗

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practiceSemantic proximity Read ↗

Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor.Semantic proximity Read ↗

Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.Semantic proximity Read ↗

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.Semantic proximity Read ↗

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Semantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.